206 related articles for article (PubMed ID: 17868472)
1. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
Serra AL; Kistler AD; Poster D; Struker M; Wüthrich RP; Weishaupt D; Tschirch F
BMC Nephrol; 2007 Sep; 8():13. PubMed ID: 17868472
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
3. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.
Riegersperger M; Herkner H; Sunder-Plassmann G
Trials; 2015 Apr; 16():182. PubMed ID: 25899445
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study.
Davis S; Gralla J; Chan L; Wiseman A; Edelstein CL
Transplant Proc; 2018 Jun; 50(5):1243-1248. PubMed ID: 29880342
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.
Wüthrich RP; Serra AL
Transplant Proc; 2009; 41(6 Suppl):S18-20. PubMed ID: 19651290
[TBL] [Abstract][Full Text] [Related]
6. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
8. [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option].
Serra AL; Wüthrich RP
Praxis (Bern 1994); 2009 Dec; 98(25):1511-6. PubMed ID: 20013687
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
Liu YM; Shao YQ; He Q
Transplant Proc; 2014; 46(1):66-74. PubMed ID: 24507028
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
12. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.
Ruggenenti P; Gentile G; Perico N; Perna A; Barcella L; Trillini M; Cortinovis M; Ferrer Siles CP; Reyes Loaeza JA; Aparicio MC; Fasolini G; Gaspari F; Martinetti D; Carrara F; Rubis N; Prandini S; Caroli A; Sharma K; Antiga L; Remuzzi A; Remuzzi G;
Clin J Am Soc Nephrol; 2016 May; 11(5):785-794. PubMed ID: 26912555
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.
Serra AL; Kistler AD; Poster D; Krauer F; Senn O; Raina S; Pavik I; Rentsch K; Regeniter A; Weishaupt D; Wüthrich RP
Nephrol Dial Transplant; 2009 Nov; 24(11):3334-42. PubMed ID: 19525519
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?
Canaud G; Knebelmann B; Harris PC; Vrtovsnik F; Correas JM; Pallet N; Heyer CM; Letavernier E; Bienaimé F; Thervet E; Martinez F; Terzi F; Legendre C
Am J Transplant; 2010 Jul; 10(7):1701-6. PubMed ID: 20642692
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
Soliman A; Zamil S; Lotfy A; Ismail E
Transplant Proc; 2012 Dec; 44(10):2936-9. PubMed ID: 23195001
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus therapy to halt the progression of ADPKD.
Perico N; Antiga L; Caroli A; Ruggenenti P; Fasolini G; Cafaro M; Ondei P; Rubis N; Diadei O; Gherardi G; Prandini S; Panozo A; Bravo RF; Carminati S; De Leon FR; Gaspari F; Cortinovis M; Motterlini N; Ene-Iordache B; Remuzzi A; Remuzzi G
J Am Soc Nephrol; 2010 Jun; 21(6):1031-40. PubMed ID: 20466742
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
He Q; Lin C; Ji S; Chen J
Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in patients with autosomal dominant polycystic kidney disease.
Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
[TBL] [Abstract][Full Text] [Related]
19. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
[TBL] [Abstract][Full Text] [Related]
20. Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.
Braun WE; Schold JD; Stephany BR; Spirko RA; Herts BR
Clin J Am Soc Nephrol; 2014 May; 9(5):881-8. PubMed ID: 24721888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
